Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2024-08-06 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
股票交易异常波动暨严重异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding abnormal and severe abnormal fluctuations in its stock price. It includes detailed explanations about the stock price movements, risk warnings to investors, references to previous announcements and reports, and clarifications about the company's current situation and disclosures. The document does not contain financial statements or detailed financial data itself but rather serves as a regulatory disclosure about stock price behavior and related risks. It also references prior reports and audit opinions but does not present them directly. The document length is 4073 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-08-06 Chinese
关于证券事务代表辞职的公告
Board/Management Information Classification · 95% confidence The document is a short announcement regarding the resignation of the company's securities affairs representative. It includes no financial data, no report content, and no mention of financial results or meetings. It is an announcement about a change in company personnel related to securities affairs, which falls under management or board information. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and does not contain any report or financial data, confirming this classification.
2024-08-02 Chinese
关于公司股价异动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It includes explanations about the stock price movements, company statements on the situation, risk warnings, and references to previously published reports such as the 2023 annual report and quarterly reports. The document does not contain actual financial statements or detailed financial data itself but rather discusses stock price movements and related company disclosures. It also references ongoing legal proceedings and risk factors. The document length is 2904 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about stock price abnormality and related disclosures, not a full financial report or earnings release.
2024-08-01 Chinese
关于TAEST16001注射液纳入突破性治疗品种名单的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the inclusion of their drug TAEST16001 injection in the breakthrough therapy designation list by the National Medical Products Administration's Drug Evaluation Center. It details the drug's development status, clinical trial results, and potential impact on the company. The document does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory announcement about a significant development related to the company's drug pipeline and regulatory status, not a financial report or management discussion. The document length is 2784 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-07-30 Chinese
第九届董事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Guangzhou Xiangxue Pharmaceutical Co., Ltd. It details the approval of a proposal to transfer 51% equity of a subsidiary to another company, including the authorization of the chairman to sign related agreements. The document includes voting results and references related announcements on a public information platform. There is no financial data, no full report, no audit, no earnings release, or other detailed financial or operational disclosures. It is clearly a Board/Management Information announcement about a corporate decision made by the board of directors.
2024-07-19 Chinese
第九届监事会第十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the approval of a related party transaction involving the transfer of subsidiary shares. It includes details of the meeting, voting results, and references to related announcements. The document is short (639 characters) and serves as an official announcement of a board decision rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous official announcements that do not fit other specific categories.
2024-07-19 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.